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Abstract
Background: Infertility affects one in seven couples; many of these need in vitro fertilisation (IVF). IVF involves
external hormones to stimulate a woman’s ovaries to produce eggs which are harvested surgically. Embryos,
created in the laboratory by mixing eggs with sperm, are grown in culture for a few days before being replaced
within the uterus (fresh embryo transfer). Spare embryos are usually frozen with a view to transfer at a later point in
time – especially if the initial fresh transfer does not result in a pregnancy. Despite improvements in technology, IVF
success rates remain low with an overall live birth rate of 25–30% per treatment. Additionally, there are concerns
about health outcomes for mothers and babies conceived through IVF, particularly after fresh embryo transfer,
including maternal ovarian hyperstimulation syndrome (OHSS) and preterm delivery. It is believed that high levels
of hormones during ovarian stimulation could create a relatively hostile environment for embryo implantation
whilst increasing the risk of OHSS. It has been suggested that freezing all embryos with the intention of thawing
and replacing them within the uterus at a later stage (thawed frozen embryo transfer) instead of fresh embryo
transfer, may lead to improved pregnancy rates and fewer complications. We aim to compare the clinical and cost
effectiveness of fresh and thawed frozen embryo transfer, with the primary aim of identifying any difference in the
chance of having a healthy baby.
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Methods: E-Freeze is a pragmatic, multicentre two-arm parallel group randomised controlled trial where women
aged ≥18 and < 42 years, with at least three good quality embryos are randomly allocated to receive either a fresh
or thawed frozen embryo transfer. The primary outcome is a healthy baby, defined as a term, singleton, live birth
with appropriate weight for gestation. Cost effectiveness will be calculated from a healthcare and societal perspective.
Discussion: E-Freeze will determine the relative benefits of fresh and thawed frozen embryo transfer in terms of
improving the chance of having a healthy baby. The results of this pragmatic study have the potential to be directly
transferred to clinical practice.
Trial registration: ISRCTN registry: ISRCTN61225414. Date assigned 29/12/2015.
Keywords: IVF, Fertility, Frozen thawed embryo transfer, Fresh embryo transfer, OHSS, Elective freezing, Assisted conception,
Receptivity
Plain English summary
Infertility is common, affecting one in seven couples in
the UK, many of whom will ultimately need in vitro fertil-
isation (IVF). IVF involves several steps; initially hormones
are used to stimulate the woman’s ovaries to produce eggs,
which are then removed through a surgical procedure.
Next, embryos are created in the laboratory by mixing
eggs with sperm. In conventional IVF, these embryos are
grown for a few days before the best available embryo is
placed inside the uterus in a process known as fresh em-
bryo transfer. Any spare embryos are then usually frozen.
Despite improvements in technology, IVF success rates
remain low and there are associated risks to women and
babies. It is thought that the high levels of hormones
used to stimulate a woman’s ovaries to produce eggs
could create a relatively hostile environment for the em-
bryo within the uterus. Freezing embryos and placing
them in the uterus at a later stage may lead to improved
pregnancy rates and fewer complications. This study
aims to compare fresh and thawed frozen embryo trans-
fer, with the main aim of identifying any differences in
the chances of having a healthy baby as well as differ-
ences in costs. The study will be available to couples at
selected fertility centres across the UK.
Background
The National Institute for Health and Care Excellence
(NICE) recommends IVF as the definitive treatment for
prolonged unresolved infertility [1]. IVF involves several
steps. Initially, hormones are used to stimulate a woman’s
ovaries to produce eggs which are harvested surgically.
Next, embryos are created in the laboratory by mixing
eggs with sperm. In conventional IVF these are grown in
culture for a few days before being replaced within the
uterus by a process known as fresh embryo transfer. Spare
embryos are usually frozen with a view to transfer at a
later point in time – especially if the initial fresh transfer
does not result in a pregnancy. Despite improvements in
technology, IVF success rates remain low with an overall
live birth rate of 25% per treatment. Additionally, there
are concerns about health outcomes for mothers and ba-
bies conceived through IVF, particularly after fresh em-
bryo transfer, including maternal ovarian hyperstimulation
syndrome (OHSS) and perinatal morbidity.
A possible cause for sub-optimal live birth rates as
well as adverse maternal and perinatal outcomes follow-
ing IVF is the impact of exogenous hormones used for
ovarian stimulation on the lining of the uterine cavity.
High levels of oestrogen produced by the ovary in re-
sponse to this treatment affect uterine receptivity, redu-
cing the chances of successful implantation and
placentation. It has been suggested that avoiding embryo
transfer at a time when the uterus is less receptive could
improve success rates. Such a strategy also reduces the
risk of OHSS by ensuring that a pregnancy does not
occur in the presence of hyperstimulated ovaries.
Preliminary data from small randomised trials from
Iran [2] and the USA [3, 4] suggest that a strategy of not
replacing embryos when they are created but freezing
them followed by thawed frozen embryo transfer into
the uterus at a later date improves pregnancy rates. A
meta-analysis of data from these three RCTs [5] has
shown higher pregnancy rates following thawed frozen
embryo transfer (odds ratio 1.32, 95% CI 1.10 to 1.59).
However, these existing trials have a number of signifi-
cant limitations:
 They reported implausibly high pregnancy rates (e.g.
84% per embryo transfer), which are far in excess of
those reported by national and international
registries.
 Key outcomes including healthy baby, live birth,
costs, safety and acceptability were not measured by
any of the trials.
 They were limited in terms of design with highly
selected populations, inadequate sample sizes and
per protocol analysis rather than by intention-to-
treat and conduct, since all involved co-
interventions which were not accounted for in the
analysis.
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One of the publications [2] has been retracted on the
grounds of serious methodological flaws. Hence, the
current evidence base comprising two small trials of
suboptimal quality is not sufficiently robust to support a
radical change in clinical practice. Additionally, their re-
sults cannot be directly applied to a UK setting due to
very different regulatory and funding arrangements.
There is, therefore, an urgent need to perform a defini-
tive randomised controlled trial in the UK evaluating
elective freezing of embryos followed by subsequent
thawed frozen embryo transfer in terms of clinical and
cost effectiveness.
A two-arm parallel group randomised controlled trial
is proposed across multiple fertility centres in the UK.
Women ≥18 and < 42 years of age undergoing their first,
second or third IVF/ICSI treatment, with at least 3 good
quality embryos will be randomised to either fresh em-
bryo transfer (standard treatment arm) or thawed frozen
embryo transfer, this typically will take place after 4 to 6
weeks and always within 3months of egg retrieval (inter-
vention treatment arm).
A single episode of thawed frozen embryo transfer
(after elective freezing of embryos) will be compared to
a single episode of fresh embryo transfer with a healthy
baby (defined as a live singleton baby born at term with
an appropriate weight for gestation) – the primary
outcome.
With 90% power and a two-sided 5% level of statistical
significance, we will need to randomise 1086 couples
(543 in each arm) to show an absolute difference in the
primary outcome of at least 9% (e.g. from 25 to 34%),
between fresh and thawed frozen embryo transfer
respectively.
A full economic evaluation will assess the costs and
consequences of the new strategy compared with standard
practice. The trial data will be combined with modelling
to estimate the long-term costs of health and social care
using a previously developed decision analytic model.
Methods/ design
A pragmatic multi-centre two-arm parallel group rando-
mised controlled trial to evaluate the effectiveness of a
policy of freezing embryos followed by thawed frozen
embryo transfer with a policy of fresh embryo transfer in
women undergoing in vitro fertilisation will be con-
ducted. All clinical elements of IVF treatment, apart
from the randomised interventions, will be carried out
according to local protocols. The trial design is sum-
marised in Fig. 1.
Number of participants
1086 couples undergoing their first, second or third
cycle of IVF/ICSI treatment will be recruited from fertil-
ity centres across the UK.
Inclusion criteria
 The female partner is ≥18 and < 42 years of age at
the start of treatment (i.e. start of ovarian
stimulation)
 Couples who are undergoing their first, second or
third cycle of IVF/ICSI treatment, where a cycle is
defined as egg collection following ovarian
stimulation.
 Both partners are resident in the UK
 Both partners are able to provide written informed
consent
 At least 3 good quality embryos (as defined by the
Association of Clinical Embryologists, UK) on day 3
after egg collection (day of egg collection is counted
as day 0). Good quality embryos on day 3 are
defined as those with 6–8 cells grade 3/3 or above
using the agreed national grading scheme [6].
Exclusion criteria
 Couples using donor gametes
 Pre-implantation genetic testing is being planned
 Elective freezing of all embryos is planned for
medical reasons (e.g. severe risk of OHSS)
 Couples previously randomised to E-Freeze
Primary outcome
The primary outcome is a healthy baby. A healthy baby is
defined as a live singleton baby born at term (between 37
and 42 completed weeks of gestation) with an appropriate
weight for gestation (weight between 10th and 90th centile
for that gestation based on standardised charts).
Secondary outcomes
The secondary outcomes relate to maternal safety, compli-
cations of pregnancy and delivery, measures of clinical ef-
fectiveness, measures of effectiveness of the process of
freezing embryos and health economic outcome measures.
Maternal safety outcome
Ovarian hyperstimulation syndrome (OHSS) – defined
and classified as per the Royal College of Obstetricians
and Gynaecologists’ Green-top Guideline [7].
Complications of pregnancy and delivery outcomes
 Vanishing twin or triplet (defined as either: more
early fetal hearts detected than babies born, more
gestational sacs than babies born or more gestational
sacs than fetal hearts detected)
 Miscarriage rate (defined as pregnancy loss prior to
24 weeks of gestation)
 Ectopic pregnancy
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 Termination
 Gestational diabetes mellitus (GDM)
 Multiple pregnancy (defined as more than one fetal
heart or more than one gestational sac detected)
 Multiple births (including live and stillbirths)
 Hypertensive disorders of pregnancy (essential
hypertension, pregnancy induced hypertension, pre-
eclampsia and eclampsia)
 Most severe hypertensive disorder (from least to
worst: essential hypertension, pregnancy induced
hypertension, pre-eclampsia and eclampsia)
 Antepartum haemorrhage (any bleeding per
vaginum after 28 weeks of pregnancy including
placenta praevia and placental abruption)
 Onset of labour (spontaneous, induced or planned
caesarean section)
 Mode of delivery for each baby (normal vaginal
delivery, instrumental vaginal delivery or caesarean
section)
 Preterm delivery (defined as delivery at < 37
completed weeks)
 Very preterm delivery (defined as delivery at < 32
completed weeks)
 Low birth weight (defined as weight < 2500 g at
birth)
 Very low birth weight (defined as weight < 1500 g at
birth)
 High birth weight (defined as weight > 4000 g at birth)
Fig. 1 E-Freeze Trial Design
Maheshwari et al. Reproductive Health           (2019) 16:81 Page 4 of 11
 Large for gestational age (defined as birth
weight > 90th centile for gestational age at
delivery, based on standardised charts)
 Small for gestational age (defined as birth
weight < 10th centile for gestational age at
delivery, based on standardised charts)
 Congenital anomaly/birth defect (all congenital
anomalies/birth defects identified will be included)
 Perinatal mortality (stillbirth or late as well as early
neonatal deaths, up to 28 days after birth)
Measures of clinical effectiveness outcomes
 Live birth rate (this is a live birth episode, i.e. twins
will count as one)
 Singleton live birth rate
 Singleton live birth rate at term
 Singleton baby with appropriate weight for gestation
 Pregnancy rate (defined as positive pregnancy test at
two weeks +/− three days after embryo transfer)
 Clinical pregnancy rate (defined as the presence of
at least one fetal heartbeat at ultrasound between six
and eight weeks of gestation; ectopic pregnancy
counts as a clinical pregnancy; multiple gestational
sacs count as one clinical pregnancy)
Measures of the effectiveness of the process of freezing
embryos outcomes
 Total number of embryos frozen, thawed and
transferred for all randomised couples
 Proportion of thawed embryos that were then
transferred for all randomised couples
 Failure of all embryos to survive after thawing
leading to no embryo transfer
Health economic outcome measures
 Cost to the health service of treatment, pregnancy
and delivery care
 Modelled long-term costs of health and social care,
and broader societal costs
Other secondary outcomes
 Evaluation of emotional state (for both the female
and male partners) when they are advised of delay in
embryo transfer in frozen arm
Study description
All couples embarking on their first, second or third
cycle of IVF/ICSI or a combination of both, will receive
a letter of invitation introducing the trial and a copy of
the Participant Information Leaflet. This will be sent
with their clinic appointment. Participant Information
Leaflets will also be distributed to couples attending an
introductory patient information session, which will
occur before their first clinic appointment. Eligible cou-
ples will be invited by a clinician involved in their care
to participate in the trial. They will have the opportunity
to speak to a research nurse to ask questions.
Consent forms need to be signed by both partners sep-
arately. This can be done at their clinic appointment or
at a subsequent visit up until but prior to the procedure
of egg collection, by an appropriately delegated member
of the team. After consent, couples will each fill in a
short questionnaire on how they are feeling emotionally.
Each participant will seal their questionnaire in an enve-
lope after completion and questionnaires will be
destroyed unopened if the couple do not proceed to ran-
domisation. Data needed for randomisation/minimisa-
tion will be recorded by the consent and randomisation
program. On the first day after egg collection the embry-
ologist or research delegate will confirm consent during
a routine phone call to the couple to discuss the out-
come of fertilisation.
On the third day after egg collection couples with at
least three good quality embryos will be randomised by
the embryologist or research nurse to fresh or thawed
frozen embryo transfer. Good quality embryos on day
three are defined as those with 6–8 cells grade 3/3 or
above using the agreed national grading scheme [6].
Couples will be informed of their randomisation alloca-
tion by the embryologist or research delegate during
their routine phone call on day three.
Couples who are randomised to thawed frozen embryo
transfer will be contacted by the research nurse or
research delegate within three working days post-
randomisation to plan thawed frozen replacement treat-
ment typically four to six weeks later and usually within
three months of egg collection.
At embryo transfer (cleavage or blastocyst for fresh, or
typically four to six weeks later for thawed frozen em-
bryo transfer but usually within three months) couples
will be asked to complete a short questionnaire to assess
additional costs related to the treatment, and to repeat
the emotions questionnaire they filled in at consent.
Women who have a positive pregnancy test two weeks
(+/− three days) after embryo transfer will be contacted
by their research nurse (by telephone) to record preg-
nancy events and outcomes at: 12 and 28 weeks of gesta-
tion and again around six weeks after delivery. Outcomes
presenting themselves >six weeks post-delivery will not be
recorded. All women who conceive by IVF/ICSI are
followed up by their IVF centres routinely, as there is a
mandatory requirement to report early pregnancy out-
comes as well as delivery outcomes to the regulatory body,
the Human Fertilisation Embryology Authority (HFEA),
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including stillbirth, congenital anomalies and perinatal
mortality. Usually this information is provided to each IVF
clinic by couples themselves. Alternatively, clinic staff con-
tact couples by telephone to collect this information to re-
port it back to the HFEA.
The participant pathway and data collection points are
shown in the Study Matrix (Fig. 2).
Ineligible and non-recruited participants
Details of all consenting couples will be entered on a
dedicated secure online database. It is anticipated that a
proportion of those consented may not proceed to ran-
domisation; the reasons for this will be recorded (if
available) including non-availability of three good quality
embryos on day three. As part of routine practice, the
embryologist contacts the couple by telephone to let
them know how many eggs are fertilised (next day after
egg collection, day one) and the quality of their embryos
(on day three after egg collection). The embryologist or
research delegate will confirm consent on day one and
inform them whether or not they fulfilled the final inclu-
sion criteria (at least three good quality embryos on day
three) and which arm they have been randomised to at
the time of their routine phone call on day three. The
research nurse will then contact the couple if they have
not fulfilled the inclusion criteria to answer any queries
and offer follow-up in the clinic. Couples not proceeding
to randomisation will be offered the most appropriate
standard treatment. All clinics have access to supportive
counselling as a mandatory requirement of the regula-
tory authority.
Randomisation
Randomisation will be performed after the creation of
embryos, three days post egg collection. This will min-
imise the randomisation-to-intervention time interval as
embryos are either transferred at the cleavage or blasto-
cyst stage. Once all eligibility criteria are established (in-
cluding ensuring that three or more good quality
embryos are available), women will be randomised (allo-
cation ratio 1:1) to a strategy of either fresh embryo
transfer or thawed frozen embryo transfer (typically four
to six weeks later and usually within three months of
egg collection).
Randomisation will be undertaken by the research
nurse or a delegated member of the research team using
a secure web-based centralised system (with 24/7 tele-
phone backup 365 days/year) hosted by the National
Perinatal Epidemiology Unit Clinical Trials Unit (NPEU
CTU), University of Oxford. The randomisation will em-
ploy a minimisation algorithm to balance across the fol-
lowing factors: fertility clinic, woman’s age (at the time
of start of treatment i.e. ovarian stimulation), primary/
secondary infertility, self-reported duration of infertility,
method of insemination (IVF/ICSI or a combination of
both) and number of previous egg collections (cycles).
Fig. 2 Study Matrix
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Treatment allocation
Blinding of the allocated intervention is not possible in this
trial because of the nature of the treatments and statutory
requirements of the regulatory body – the HFEA. Discus-
sion with the couple about the time and day of embryo
transfer is routinely conducted over the telephone on the
third day after fertilisation of eggs in the laboratory in all
IVF clinics as part of routine care. A member of the IVF la-
boratory (embryology) team or research delegate will in-
form consented eligible couples on day three of the
outcome of randomisation over the telephone.
The process will be as follows:
 Standard care arm: Women will undergo fresh
embryo transfer at the cleavage or blastocyst stage
according to local protocols.
 Intervention arm: All good quality embryos will be
frozen according to local protocols. Women will be
contacted by their research nurse after
randomisation and arrangements will be made for
thawed frozen embryo transfer (typically this takes
place within 4 to 6 weeks and usually within three
months of the egg retrieval process). This will
involve a few visits to hospital to prepare the
endometrium.
Withdrawal procedures
Couples will be able to withdraw their consent to take
part in the trial at any time without giving a reason.
Withdrawal from the intervention/study will not affect
their ongoing care. Non-adherence to the allocated
intervention may also occur; this is defined as a differ-
ence between the treatment allocation provided at ran-
domisation and the allocation received by the woman at
the time of embryo transfer. Non-adherence to the allo-
cated intervention may occur if the clinician feels it is in
the couple’s best interests, e.g. freezing all created em-
bryos is necessary for medical reasons, or transferring
fresh embryos for clinical reasons. In the case of a
non-adherence to the allocated intervention, the couple,
with their on-going consent, would continue to be part
of the trial, with outcome data collected in the routine
manner.
Safety reporting
Foreseeable serious adverse events (SAEs) are those
events which are expected in the patient population or
as a result of the routine care/treatment of a patient.
Foreseeable SAEs will be collected on the electronic
Case Report Form (eCRF) as part of routine data collec-
tion. The following events are foreseeable in women or
couples undergoing IVF treatment and as such do not
require reporting as SAEs.
Foreseeable events relating to the female partner, or
couple:
 Ovarian hyperstimulation syndrome (OHSS)
 Miscarriage
 Hypertensive disorders of pregnancy
 Antepartum haemorrhage
 Gestational diabetes mellitus (GDM)
 Multiple pregnancy
 Failure of any embryos to survive thawing
Foreseeable events relating to the baby, when born:
 Low birth weight
 Very low birth weight
 Large for gestational age
 Preterm delivery
 Very preterm delivery
 Small for gestational age
Unforeseeable serious adverse events
An unforeseeable SAE is any event that meets the defin-
ition of a SAE and is not detailed in the list above as
foreseeable. The following unforeseeable SAEs must be
reported:
 Maternal death
 Stillbirth
 Congenital anomaly detected antenatally or
postnatally
 Neonatal death
Unforeseeable SAEs will be reported up to six weeks
post-delivery.
Data collection
Data for both clinical and economic outcomes will be
collected using bespoke electronic case report forms
(eCRFs) and entered directly into the trial’s OpenClinica
electronic database by the IVF centre’s research staff.
Data will be single-entered and at the point of entry the
data will undergo a number of validation checks to ver-
ify the validity and completeness of the data captured.
Sample size calculation
The proposed primary outcome for this trial is novel
and is not currently reported by IVF clinics or national
regulatory bodies. This means that a number of assump-
tions have been made in order to determine the ex-
pected event rate in the control arm (receiving current
standard treatment), which may in turn result in a de-
gree of imprecision in the estimate.
The data from the HFEA [8], which collects data on
all IVF cycles from all clinics in the UK, show that 25%
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of all women undergoing one episode of IVF treatment
involving a fresh embryo transfer have a live birth, and
20% have singleton live births. These figures are for
women of all age groups, not necessarily for women ful-
filling the inclusion criteria for this trial in terms of the
number of good quality embryos in their IVF cycle. No
data are available regarding the healthy baby rate (live
singletons born between 37 and 42 weeks with appropri-
ate weight for gestation), the primary outcome for this
study. For our trial population we anticipate that the
control arm event rate is likely to be less than 25%, pos-
sibly as low as 17%. Although the live birth rate is ex-
pected to be higher in women with at least three good
quality embryos (likely to have a better prognosis), we
anticipate that the healthy baby rate in our trial popula-
tion will be towards the lower end of the confidence
interval, around 25%, taking into account the higher risk
of preterm delivery and small for gestational age babies
following IVF [9].
The following assumptions have been made for the sample
size calculation
We have assumed a healthy baby rate of between 17%
and 25% in women eligible for the trial (age under 42
years with three good quality embryos) undergoing
standard care (fresh embryo transfer). Taking into ac-
count the extra time, effort and potential expense in-
volved in freezing embryos and the delay in embryo
transfer of up to three months, a panel of clinicians
across the UK agreed that the strategy of freezing em-
bryos would be considered clinically effective if the per-
centage of women having a healthy baby is increased by
at least 8% in absolute terms. With 90% power and using
a two-sided 5% level of statistical significance, we will
need to randomise a total of 1086 couples (543 in each
group) in order to be able to detect an absolute differ-
ence of 8% from 17% to 25% and 9% from 25% to 34%
in the healthy baby rate, between fresh embryo transfer
and transfer of thawed frozen embryos. The difference
detectable differs slightly depending on the event rate in
the standard care group, which will be reviewed period-
ically by the Data Monitoring Committee (DMC).
It is a regulatory requirement for clinics in the UK to
report live birth outcomes (including number, weight,
gestation and gender) to the HFEA after all embryo
transfers i.e. there will be no loss to follow-up. There-
fore, we have not taken into account loss to follow-up
for these sample size calculations. It is anticipated that a
proportion of those consented may not reach random-
isation (e.g. those not having three good quality day
three embryos or requiring all embryos to be frozen for
medical reasons); therefore a higher number will need to
be consented.
Analysis
A detailed Statistical Analysis Plan (SAP) will be devel-
oped and agreed by the Trial Steering Committee (TSC)
before the analysis is undertaken. The analysis and pres-
entation of results will follow the most up-to-date rec-
ommendations of the CONSORT group. Baseline
demographic factors and clinical characteristics of the
woman will be summarised with counts and percentages
for categorical variables, means (with standard devia-
tions) for normally distributed continuous variables, or
medians (with interquartile ranges) for other continuous
variables.
All outcomes will be analysed in the groups to which
they are assigned, regardless of deviation from the proto-
col or treatment received under the intention-to-treat
analysis principle. All comparative analyses will adjust
for the minimisation factors wherever possible. Binary
outcomes will be analysed using a log binomial regres-
sion model, or using a log Poisson regression model with
a robust variance estimator if the binomial model fails to
converge. Linear regression will be used for normally
distributed continuous outcomes and quantile regression
for skewed continuous outcomes. Comparative analyses
will entail calculating the adjusted risk ratio (RR) and
95% confidence interval (CI) for the primary outcome,
adjusted RRs and 99% CIs for all binary secondary out-
comes, adjusted mean differences (with a 99% CI) for
normally distributed continuous secondary outcomes, or
median differences (99% CI) for skewed continuous sec-
ondary outcome variables (unless the data can be trans-
formed to normality). For neonatal secondary outcomes
(e.g. low birth weight, small for gestational age, congeni-
tal anomaly and perinatal mortality) the adjusted analysis
will also account for the anticipated correlation in out-
comes between multiple births.
Pre-specified subgroup analysis
The consistency of the effect of electively freezing em-
bryos followed by thawed frozen embryo transfer on the
primary outcome across specific subgroups will be
assessed using the statistical test for interaction.
Pre-specified subgroup analyses are (i) woman’s age (test
for trend), (ii) fertility clinic, (iii) cleavage vs blastocyst
embryo transfer, (iv) single vs multiple embryo transfer,
(v) number of previous embryo transfer cycles.
Secondary analysis
The primary analysis for all primary and secondary out-
comes will be by intention-to-treat. Secondary analyses
will be performed to include the clinically relevant de-
nominators as shown in Table 1. In addition, failure of
embryos to survive after thawing (per embryo thawed)
will be reported for the intervention group.
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Economic evaluation
A formal economic evaluation will be undertaken to assess
the cost effectiveness of the alternative approaches to treat-
ment used in the trial. Resource use and costs will be esti-
mated primarily from a health and personal social services
perspective. However, personal time and travel costs, asso-
ciated with any additional treatment-related visits which are
not part of standard routine practice, will also be estimated
via a short questionnaire administered at the time of em-
bryo transfer. This is to be completed by both partners. In
addition, longer-term social costs associated with child
health outcomes will be modelled based on existing litera-
ture. Trial data collection instruments (eCRFs) will be used
to capture participant level resource use associated with
treatment, up to the trial end points of delivery or failure to
become pregnant following the initial transfer. Appropriate
unit costs [10, 11] will be used to value resource use events
recorded in the case report forms. These costs will be sum-
marised by treatment allocation group (by intention-
to-treat), and presented in relation to the primary and sec-
ondary clinical outcomes. A cost-consequence balance
sheet will be constructed to highlight the favoured strategy
on cost and each clinical outcome at 12months. The extra
cost per additional healthy baby delivered (in the thawed
frozen embryo transfer group versus fresh embryo transfer)
will also be estimated using linear regression with adjust-
ment for minimisation variables and baseline covariates as
appropriate.
Many couples who fail to conceive following the initial
embryo transfer will have access to subsequent frozen/
thawed transfers, although the costs and outcomes asso-
ciated with these will not be captured within the trial
follow-up. Additionally, some adverse birth outcomes
(e.g. preterm delivery, low birth weight) can have a
far-reaching impact on costs and child health outcomes.
Modelling will therefore be used to inform cost effect-
iveness over an extended time horizon. In order to do
this, we will adapt an existing decision model [12] to
simulate the progression of couples (who do not experi-
ence live birth following their initial embryo transfer) to
the subsequent transfer of their remaining frozen
embryos.
The model will also capture the longer-term cost and
quality of life outcomes for any infants born as a result of
treatment. The outputs of this modelling exercise will also
be presented in the form of a cost-consequence balance
sheet. Deterministic and probabilistic sensitivity analyses
will be undertaken to characterise the uncertainty sur-
rounding the estimated differences in costs and outcomes
between approaches, and to assess the impact of changes
in key model input parameters and assumptions.
Study management and oversight arrangements
Trial Steering Committee (TSC)
The role of the TSC is to provide the overall supervision
of the study. The TSC should monitor the progress of
the study and conduct and advise on its scientific cred-
ibility. The TSC will consider and act, as appropriate,
upon the recommendations of the Data Monitoring
Committee (DMC) and ultimately carries the responsi-
bility for deciding whether a trial needs to be stopped on
grounds of safety or efficacy.
Data Monitoring Committee (DMC)
A DMC independent of the applicants and the TSC will
review the progress of the trial at least annually and
Table 1 Secondary analysis
Outcome Clinically relevant Denominator
Miscarriage rate per total number of women with a positive pregnancy test at two weeks +/− three days
after embryo transfer
Multiple pregnancy per total number of pregnant women with an ongoing pregnancy resulting in delivery
Gestational diabetes mellitus per total number of pregnant women with an ongoing pregnancy resulting in delivery
Hypertensive disorders per total number of pregnant women with an ongoing pregnancy resulting in delivery
Antepartum haemorrhage per total number of pregnant women with an ongoing pregnancy resulting in delivery
Preterm delivery (< 37 completed weeks) per total number of pregnant women with an ongoing pregnancy resulting in delivery
Very preterm delivery (< 32 completed weeks) per total number of pregnant women with an ongoing pregnancy resulting in delivery
Low birth weight (< 2500 g at birth) per total number of babies born
Very low birth weight (< 1500 g at birth) per total number of babies born
High birth weight (> 4000 g at birth) per total number of babies born
Large for gestational age (>90th centile) per total number of babies born
Small for gestational age (<10th centile) per total number of babies born
Congenital anomaly/birth defect per total number of babies born
Perinatal mortality per total number of babies born
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provide advice on the conduct of the trial to the TSC
who will report to the Health Technology Assessment
(HTA) programme manager. The committee will period-
ically review study progress and outcomes. The DMC
will consist of an independent chair and at least two
other independent members, who will be experts in their
field, such as an embryologist, statistician or IVF
clinician.
Project Management Group (PMG)
The study will be supervised on a day-to-day basis by
the Project Management Group (PMG). This group re-
ports to the TSC, which has overall responsibility for the
conduct of the study. The PMG will meet regularly (at
least monthly).
Trial Management
The trial co-ordinating centre will be at the NPEU CTU,
University of Oxford, where the Trial Manager will be
based. The NPEU CTU will be responsible for trial over-
sight, IT system/functions such as randomisation, clin-
ical and administrative databases, all programming and
statistical analyses, servicing both the DMC and TSC,
and, in collaboration with the Chief Investigator and the
Local Research Nurse for the general day-to-day running
of the study including recruitment of sites and training
of staff. A 24/7 (365 days a year) emergency helpline is
available for out-of-hours queries relating to the trial.
The economic analysis will be conducted at the Univer-
sity of Aberdeen.
Risk Assessment and Monitoring
A study risk assessment and monitoring plan has been
completed as part of the development of this study by
NPEU CTU. This risk assessment and monitoring plan
will be reviewed at regular intervals during the course of
the study to ensure that appropriate and proportionate
monitoring activity is performed.
Confidentiality, data protection and data management
Direct access to source data/documents (including hos-
pital records/notes, clinical charts, laboratory reports,
pharmacy records and test reports) will be granted to
authorised representatives from the NPEU CTU, the
Sponsor and host organisations to permit study related
monitoring, audits and inspections.
Overall responsibility for ensuring that each partici-
pant’s information is kept confidential will lie with the
study Sponsor who has delegated this responsibility to
the NPEU CTU. All paper documents will be stored se-
curely and kept in strict confidence in compliance with
the Data Protection Act (2018). Data entered onto the
eCRFs will be automatically transferred for storage in an
electronic database hosted by NPEU CTU on behalf of
the Sponsor, in which the participant will be identified
only by a study specific number. The participant’s name
and any other identifying details will be stored in a sep-
arate database also held by NPEU CTU on behalf of the
Sponsor which will be linked to the database containing
study data only by the participant’s study number. After
the study has been completed and the reports published,
the data will be archived. Electronic and paper docu-
ments will be archived by the NPEU using their secure
archiving facilities, as detailed in NPEU Standard Oper-
ating Procedures.
Electronic files will be stored on a file server that has
restricted access. The server is in a secure location and
access is restricted to a few named individuals. Access to
the building in which the NPEU CTU is situated is via
an electronic tag and individual rooms are kept locked
when unoccupied. Authorisation to access restricted
areas of the NPEU CTU network is as described in the
NPEU CTU security policy. Data will be processed on a
workstation by authorised staff. The computer worksta-
tions access the network via a login name and password
(changed regularly). No data are stored on individual
workstations. Backing up is done automatically over-
night to an offsite storage area. The location of the
backup computer is in a separate department which has
electronic tag access. Access to the room in which the
backup machine is located is via a keypad system.
Practical considerations
In order to participate in the trial, couples should have
at least three good quality embryos on day three after
egg collection. This is to ensure that they have enough
embryos to survive the freezing/thawing process. The
risk of failure of an embryo to survive thawing is min-
imal and the requirement to have at least three embryos
should make the risk negligible. As there are no available
data on the likelihood to achieve three good quality em-
bryos, the impact on recruitment is unknown, however
it is anticipated that at least half of those consented will
not progress to take part in the trial.
There may be a long gap between consent and ran-
domisation (Fig. 2). An individual’s medical and personal
situation can change in between; hence there will be an
expected drop out between consent and randomisation.
This will be in addition to those who will not have three
good quality embryos.
There will be no restriction of NHS or private sites.
All couples will be entitled to participate, if they fulfil
the inclusion criteria and they are having treatment in a
clinic that is participating in the trial. There will be no
extra cost to the patients participating in the trial even if
they are funding their IVF treatment themselves.
Although this trial will only compare one fresh versus
one thawed frozen embryo transfer, couples will be
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consented for follow-up. For those who consent to
follow-up, we will report on cumulative live birth rate
and long term outcomes of babies born (with appropri-
ate approvals).
Discussion
There is widespread interest in embryo freezing and a pol-
icy of freezing all embryos is increasingly being adopted
globally. Although there are published trials, E-Freeze is
specific to population and policies in the UK. This is a
pragmatic trial; we expect that results will influence na-
tional guidance for practice to a wider group rather than a
restricted group. To ensure this, IVF clinics continue with
their normal processes of stimulation regimens, freezing
protocols and embryo transfer policies. This will encour-
age more clinics to take part in the trial.
The aim of IVF is a healthy baby. This is the only trial
with this outcome comparing fresh versus thawed frozen
embryo transfer. The trial is also unique in exploring
broader considerations, including both the emotional fac-
tors associated with the wait linked to embryo freezing
and the cost both in terms of freezing processes and add-
itional clinic visits for the couple. This will be the first trial
in the world to explore and model the long term costs as-
sociated with a policy of freezing embryos and transferring
later both from a healthcare and societal perspective.
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